Change of management at Oettinger Davidoff AG
Basel, Switzerland, 28 August 2017 – After ten years on the Board of Directors of Oettinger Davidoff AG, Andreas Schmid (60), company Chairman and shareholder, will leave the company in order to concentrate on his other roles at various globally active firms and on his own business activities. The Board of Directors of Oettinger Davidoff AG has nominated Domenico Scala (52) as the new Chairman.
Domenico Scala was responsible as CFO of Syngenta and CEO of Nobel Biocare. Until May 2016,he chaired the independent Audit & Compliance Committee of FIFA. Currently, he is the Chairman of Basilea Pharmaceutica, BAK Basel Economics as well as the President of BaselArea, a Member of the Board of Overseers of Tufts University in Boston and a member of the Bank Council of Basler Kantonalbank.
As part of the ongoing rejuvenation of the operational management, the Board of Directors has also appointed Beat Hauenstein (50), former COO of the Group, as the new CEO. Hauenstein succeeds Hans-Kristian Hoejsgaard (59), who has decided to leave the company he has led for seven years in order to concentrate on his board and consultancy mandates outside the company. The Board of Directors would like to thank Andreas Schmid and Hans-Kristian Hoejsgaard for their many years of successful work for the company, and wishes both of them all the best for their personal and professional future.